Is Lixte Biotechnology Holdings, Inc. (LIXT) a Buy, Sell, or Hold?
NASDAQ : LIXT
Lixte Biotechnology Holdings, Inc.
$7.21 USD
-$0.46 (-6.0%)
- Volume
- 615.06K
- Average Volume
- 238.6K
- Market Capitalization
- $89.11M
- P/E Ratio
- -6.38
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $8.38
- Year Low
- $2.02
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.78
Company Overview
NASDAQ
Geordan G. Pursglove
Biotechnology
Healthcare
LIXT
3
US
USD
Liquidity Metrics
0.13
2.78
2.78
2.65
0.00
Sales & Valuation
-$
0.00
9.88
-20.45
-0.40
Profitability
-$1.26
-$6.01M
0.00%
0.00%
-125.56%
-66.95%
P/E Metrics
-6.38
-0.26
-0.26
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
21.98
1/9
$2.18M
$10.87M
$1.69M
-$7.33M
Key Metrics (TTM)
$86.92M
0.00
-11.86
2.78
-125.56%
-62.41%
-9.27%
-4.89%
0 days
Company Executives
| Name | Title |
|---|---|
| Bastiaan van der Baan | Chief Scientific Officer |
| Braxten Gorrill | Chief Financial Officer |
| Chris McKay | Chief Operating Officer |
| John Francis Travaglini | CEO & President |
| Peter Stazzone | Chief Financial Officer |
| Geordan G. Pursglove | Chief Executive Officer, President & Chairman |
Poll Results
No votes yet today — be the first to share your view!
About Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Stock
Lixte Biotechnology Holdings, Inc. is a drug discovery company focused on developing new treatments. It employs biomarker technology to identify crucial enzyme targets associated with serious, widespread diseases, then designs innovative compounds to act upon these targets. The company's primary focus lies in protein phosphatase inhibitors, which are being investigated for use both independently and in combination with cytotoxic agents, radiation therapy, and immune checkpoint blockers. Its pipeline includes two main categories of compounds, currently in various stages of pre-clinical and clinical development. The LB-100 series consists of novel chemical entities aimed at treating various cancers, vascular diseases, and metabolic disorders. Meanwhile, the LB-200 series is being developed t ... o address chronic hereditary conditions, such as Gaucher's disease, as well as specific cancers and neurodegenerative ailments. Lixte Biotechnology Holdings, Inc. has forged significant alliances, including a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc. Additionally, it has collaboration agreements for investigator-initiated clinical trials with the Spanish Sarcoma Group, the Netherlands Cancer Institute, and the Oncode Institute. Founded in 2005, the company is headquartered in Pasadena, California.
2026-07-06 11:40:00
Issued on behalf of NOMAD Power Solutions, Inc. (Nasdaq: NMAD), formerly LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) NOMAD Power Solutions, Inc. has completed its corporate name change from LIXTE Biotechnology Holdings, Inc. and begins trading today under the new Nasdaq ticker NMAD, marking its transition into the AI energy infrastructure equipment and services sector following its acquisition of NOMAD Transportable Power Systems American News Group News Commentary BOCA RATON, Fla., July 6, 2026 /PRNewswire/ -- The artificial intelligence buildout has run headlong into a physical bottleneck: electricity.
2026-07-06 08:30:00
-- New Corporate Identity Reflects Strategic Transition into AI Energy Infrastructure Equipment & Services Sector Following Acquisition of NOMAD Transportable Power Systems -- BOCA RATON, Fla., July 06, 2026 (GLOBE NEWSWIRE) -- NOMAD Power Solutions, Inc. (“NOMAD” or the “Company”), today announced that it has completed its name change from LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) to NOMAD Power Solutions, Inc (Nasdaq: NMAD).
2026-07-06 08:30:00
-- New Corporate Identity Reflects Strategic Transition into AI Energy Infrastructure Equipment and Services Sector Following Acquisition of NOMAD Transportable Power Systems -- BOCA RATON, Fla. , July 06, 2026 (GLOBE NEWSWIRE) -- NOMAD Power Solutions, Inc. ("NOMAD" or the "Company"), today announced that it has completed its name change from LIXTE Biotechnology Holdings, Inc.
LIXTE COMPLETES MERGER WITH NOMAD TRANSPORTABLE POWER SYSTEMS
2026-07-02 08:30:00
-Transaction Transforms LIXTE to New Growth Sector Addressing Multi-Billion-Dollar Market of Mobile, Utility-Grade Battery Energy Storage Systems- -Company Plans Corporate Name Change to NOMAD Power Solutions
LIXTE COMPLETES MERGER WITH NOMAD TRANSPORTABLE POWER SYSTEMS
2026-07-02 08:30:00
-Transaction Transforms LIXTE to New Growth Sector Addressing Multi-Billion-Dollar Market of Mobile, Utility-Grade Battery Energy Storage Systems- -Company Plans Corporate Name Change to NOMAD Power Solutions BOCA RATON, Fla. /WATERBURY, Vt. , July 02, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT) ("LIXTE" or the "Company") today announced it has completed the previously announced merger with NOMAD Transportable Power Systems, Inc.
LIXTE Joins Russell Microcap Index
2026-06-26 08:30:00
BOCA RATON, Fla. , June 26, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT), today announced its inclusion in the Russell Microcap Index, effective after the close of the U. S. equity markets on June 26, 2026, as part of the annual Russell U.
LIXTE Joins Russell Microcap Index
2026-06-26 08:30:00
BOCA RATON, Fla., June 26, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), today announced its inclusion in the Russell Microcap® Index, effective after the close of the U.S. equity markets on June 26, 2026, as part of the annual Russell U.S. Indexes reconstitution. The reconstituted indexes will take effect at the opening of trading on Monday, June 29, 2026.
2026-06-18 08:30:00
Company to Loan $6.5 Million Prior to Closing to Fund Order Backlog and Working Capital Needs – Combined Company to be Renamed NOMAD Power Solutions, Inc. and Trade Under a New Ticker Symbol BOCA RATON, Fla. & WATERBURY, Vt.
Frequently Asked Questions
-
What is the current Lixte Biotechnology Holdings, Inc. (LIXT) stock price?
-
Lixte Biotechnology Holdings, Inc.(NASDAQ:LIXT) stock price is $7.21 in the last trading session. During the trading session, LIXT stock reached the peak price of $8.38 while $2.02 was the lowest point it dropped to. The percentage change in LIXT stock occurred in the recent session was --6.0% while the dollar amount for the price change in LIXT stock was -$0.46.
-
LIXT's industry and sector of operation?
-
The NASDAQ listed LIXT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of LIXT?
-
Bastiaan van der Baan | Chief Scientific Officer
Braxten Gorrill | Chief Financial Officer
Chris McKay | Chief Operating Officer
John Francis Travaglini | CEO & President
Peter Stazzone | Chief Financial Officer -
How many employees does LIXT have?
-
Number of LIXT employees currently stands at 3. LIXT operates from 680 East Colorado Boulevard, Boca Raton, FL 91101, US.
-
Link for LIXT official website?
-
Official Website of LIXT is: https://lixte.com
-
How do I contact LIXT?
-
LIXT could be contacted at phone #631 830 7092 and can also be accessed through its website. LIXT operates from 680 East Colorado Boulevard, Boca Raton, FL 91101, US.
-
How many shares of LIXT are traded daily?
-
The average number of LIXT shares traded daily for last 3 months was 238.6K.
-
What is the market cap of LIXT currently?
-
The market value of LIXT currently stands at $89.11M with its latest stock price at $7.21